Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 2, 2011, Pages 475-479

  Xu, Xin Hua ^a   Su, Jin ^a   Fu, Xiang Yang ^a   Xue, Feng ^a   Huang, Qiao ^a   Li, Dao Jun ^a   Lu, Ming Qian ^a  

^a CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

Elderly patients; Erlotinib; Lung carcinoma; Non small cell lung cancer

Indexed keywords

ERLOTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; ADVANCED CANCER; AGED; ARTICLE; ASIAN; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; GERIATRIC PATIENT; HEMOPTYSIS; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; ASIA; CLINICAL TRIAL; ETHNOLOGY; KAPLAN MEIER METHOD; LUNG TUMOR; MORTALITY; SEXUAL DEVELOPMENT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; QUINAZOLINES; SEX CHARACTERISTICS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79953785851     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1450-6     Document Type: Article

References (16)

1. Jemal A, Siegel R, Ward E, Murray T et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106-130
2. D'Addario G, Felip E, ESMO Guidelines Working Group (2009) Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:68-70
3. Pfister DG, Johnson DH, Azzoli CG et al (2004) American Society of Clinical Oncology: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330-353 (Pubitemid 41095099)
4. Wakelee H, Belani CP (2005) Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 10:1-10 (Pubitemid 43152725)
5. Jemal A, Siegel R, Ward e et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66 (Pubitemid 46148091)
6. Repetto L, Venturino A, Fratino L et al (2003) Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 39:870-880 (Pubitemid 36428618)
7. Gridelli C, Perrone F, Gallo C et al (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372 (Pubitemid 36395256)
8. Burris HA, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-time therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
9. Shepherd FA, Pereira JR, Ciuleanu T et al (2005) Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
10. Jackman DM, Yeap BY, Lindeman NI et al (2007) Phase II clinical trial of chemotherapy naive patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25:760-766 (Pubitemid 350002874)
11. Merimsky O, Cheng CK, Reck M et al (2008) Erlotinib: evaluation as a first-line treatment option for elderly patients with advanced non-small-cell lung cancer (NSCLC). Oncology/Hematology 68: S26
12. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500 (Pubitemid 38720929)
13. Sequist LV, Martins RG, Spigel D et al (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442-2449
14. Miller VA, Riely GJ, Zakowski MF et al (2008) Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26:1472-1478
15. Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353:133-144 (Pubitemid 41058345)
16. Tsao MS, Aviel-Ronen S, Ding K et al (2007) Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 25:5240-5247 (Pubitemid 350232256)